Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SS)
Guangzhou, CN
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along with its various subsidiaries, operates as a comprehensive pharmaceutical enterprise. It is actively engaged in the research, development, production, and distribution of a wide array of products, including traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials, natural and biological medications, and chemical raw material intermediates. Its operations span both the People's Republic of China and international markets. The company structures its extensive operations into four primary segments: Great Southern TCM, Great Commerce, Great Health, and a miscellaneous 'Others' category. Beyond its core pharmaceutical manufacturing, GBPHCL's activities extend to the wholesale, retail, import, and export of both Western and traditional Chinese medicines, as well as medical apparatus and instruments. Furthermore, its diverse product portfolio encompasses the research, development, production, and sale of consumer health items such as beverages, various food products (including pre-packaged items and dairy), and a broad range of pharmaceutical formulations like tablets, capsules, lozenges, injections, and even traditional specialties like tortoise herb jelly. The group also strategically invests in the broader health industry, focusing on areas like medical care, health management, health preservation, and elderly care. Complementing these activities, it offers commercial and advertising services. As of December 31, 2021, GBPHCL maintained a substantial retail presence, operating 154 chain pharmacy outlets. This network comprised 22 Cai Zhi Lin pharmacies, 36 Jian Min pharmacies, 51 GPC Prescription Pharmacy locations, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets, alongside an additional 22 general retail stores. Tracing its origins back to its incorporation in 1997, the company was initially known as Guangzhou Pharmaceutical Company Limited. It adopted its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. The company is headquartered in Guangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.80% | -0.60% | -4.99% | -14.91% | -16.59% | -16.39% | -20.38% | -40.39% | -33.33% | -6.52% | +324.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.3% Q1'26: +3.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+5.2% Q1'26: -1.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.0% Q1'26: -10.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.0% Q1'26: +9.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+7.0% ★ Q1'26: +13.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.10× ★ Q1'26: 2.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.12B
est: 20.26B (-5.6%)
|
20.04B
est: 20.19B (-0.8%)
|
20.95B
est: 20.51B (+2.2%)
|
42.23B
est: 41.15B (+2.6%)
|
64.95B
est: 63.16B (+2.8%)
|
61.67B
est: 63.36B (-2.7%)
|
69.01B
est: 68.94B (+0.1%)
|
70.79B
est: 71.59B (-1.1%)
|
75.52B
est: 75.00B (+0.7%)
|
74.99B
est: 76.06B (-1.4%)
|
77.45B
est: 78.60B (-1.5%)
|
81.53B
81.33B – 81.86B
+3.7% YoY
|
85.51B
84.37B – 86.61B
+4.9% YoY
|
89.63B
87.84B – 91.43B
+4.8% YoY
|
| EBITDA |
1.39B
est: 1.28B (+8.8%)
|
1.40B
est: 1.28B (+9.6%)
|
2.16B
est: 1.30B (+66.5%)
|
2.68B
est: 2.60B (+3.0%)
|
3.90B
est: 3.99B (-2.4%)
|
3.42B
est: 4.01B (-14.8%)
|
4.39B
est: 4.36B (+0.7%)
|
5.00B
est: 4.53B (+10.5%)
|
5.46B
est: 4.74B (+15.2%)
|
4.07B
est: 4.77B (-14.6%)
|
4.06B
est: 4.92B (-17.6%)
|
5.11B
5.10B – 5.13B
+3.7% YoY
|
5.36B
5.29B – 5.43B
+4.9% YoY
|
5.62B
5.50B – 5.73B
+4.8% YoY
|
| EBIT |
1.18B
est: 1.13B (+3.7%)
|
1.16B
est: 1.13B (+3.0%)
|
1.92B
est: 1.15B (+66.8%)
|
2.38B
est: 2.30B (+3.3%)
|
3.52B
est: 3.53B (-0.4%)
|
3.03B
est: 3.55B (-14.7%)
|
3.97B
est: 3.86B (+2.9%)
|
4.49B
est: 4.01B (+12.0%)
|
4.80B
est: 4.20B (+14.3%)
|
3.47B
est: 4.12B (-15.7%)
|
3.10B
est: 4.26B (-27.1%)
|
4.42B
4.40B – 4.43B
+3.7% YoY
|
4.63B
4.57B – 4.69B
+4.9% YoY
|
4.85B
4.76B – 4.95B
+4.8% YoY
|
| Net Income |
1.30B
est: 1.72B (-24.6%)
|
1.51B
est: 1.55B (-2.6%)
|
2.06B
est: 1.87B (+10.1%)
|
3.44B
est: 3.64B (-5.5%)
|
3.19B
est: 3.46B (-7.8%)
|
2.92B
est: 2.89B (+1.0%)
|
3.72B
est: 3.64B (+2.3%)
|
3.97B
est: 3.84B (+3.2%)
|
4.06B
est: 4.35B (-6.8%)
|
2.84B
est: 3.49B (-18.7%)
|
2.98B
est: 3.20B (-6.8%)
|
3.14B
3.13B – 3.16B
-1.8% YoY
|
3.31B
3.27B – 3.35B
+5.2% YoY
|
3.58B
3.54B – 3.62B
+8.2% YoY
|
| SGA |
5.43B
est: 2.22B (+144.4%)
|
5.18B
est: 2.21B (+133.8%)
|
5.40B
est: 2.25B (+140.2%)
|
6.58B
est: 4.51B (+45.9%)
|
7.63B
est: 6.93B (+10.2%)
|
6.35B
est: 6.95B (-8.7%)
|
7.90B
est: 7.56B (+4.4%)
|
8.01B
est: 7.85B (+2.0%)
|
8.45B
est: 8.23B (+2.7%)
|
7.95B
est: 8.32B (-4.4%)
|
7.86B
est: 8.60B (-8.6%)
|
8.92B
8.90B – 8.95B
+3.7% YoY
|
9.35B
9.23B – 9.47B
+4.9% YoY
|
9.80B
9.61B – 10.00B
+4.8% YoY
|
| EPS |
1.01
est: 1.06 (-4.7%)
|
1.08
est: 0.95 (+13.4%)
|
1.27
est: 1.15 (+10.3%)
|
2.12
est: 2.24 (-5.4%)
|
1.96
est: 2.13 (-7.8%)
|
1.79
est: 1.78 (+0.8%)
|
2.29
est: 2.24 (+2.4%)
|
2.44
est: 2.36 (+3.2%)
|
2.49
est: 2.68 (-6.9%)
|
1.74
est: 2.14 (-18.9%)
|
1.83
est: 1.97 (-7.0%)
|
1.93
1.92 – 1.94
-1.8% YoY
|
2.03
2.01 – 2.06
+5.2% YoY
|
2.20
2.18 – 2.22
+8.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.13% | 48.7K | 0.65% |
| 2 | HSBC MSCI China A UCITS ETF HMCT.L | 0.10% | 139.1K | 0.30% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.05% | 7.6K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 26.7K | 0.55% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.02% | 262.7K | 0.19% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 41.5K | 0.19% |
| 7 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.01% | 5.3K | 0.19% |
| 8 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 559.9K | 0.06% |
| 9 | Franklin FTSE Asia ex Japan ETF FLAX | 0.00% | 2.2K | 0.19% |
| 10 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 14.0K | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongjin Cheng | Executive Director | 2M | male |
| Heping Tang | Executive Director | 2M | male |
| Hong Li | GM & Executive Director | 1M | male |
| Haoshan Zheng | Deputy GM & Director of Business Administration Department | — | female |
| Jiehui Chen | Executive Vice Chairman of the Board | — | male |
| Liu Fei | Chief Financial Officer | — | female |
| Xuezhen Huang | Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600332.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
